PI3K regulatory subunits lose control in cancer.

Abstract:

:The PI3K signaling axis is frequently activated in cancer resulting from inactivation of its negative regulator PTEN or activating mutations of the p110alpha catalytic subunit of PI3K. In this issue of Cancer Cell, Jaiswal et al. report that mutations in the p85alpha regulatory subunit of PI3K can also activate this pathway in cancer.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Berenjeno IM,Vanhaesebroeck B

doi

10.1016/j.ccr.2009.11.017

subject

Has Abstract

pub_date

2009-12-08 00:00:00

pages

449-50

issue

6

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(09)00393-6

journal_volume

16

pub_type

评论,杂志文章
  • A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

    abstract::Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissect...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.10.018

    authors: Mok SC,Bonome T,Vathipadiekal V,Bell A,Johnson ME,Wong KK,Park DC,Hao K,Yip DK,Donninger H,Ozbun L,Samimi G,Brady J,Randonovich M,Pise-Masison CA,Barrett JC,Wong WH,Welch WR,Berkowitz RS,Birrer MJ

    更新日期:2009-12-08 00:00:00

  • M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.

    abstract::In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction nee...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2019.06.004

    authors: Srour N,Mersaoui SY,Richard S

    更新日期:2019-07-08 00:00:00

  • Cell signaling and cancer.

    abstract::During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, an...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(03)00216-2

    authors: Martin GS

    更新日期:2003-09-01 00:00:00

  • Synergy between PPARgamma ligands and platinum-based drugs in cancer.

    abstract::PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specifi...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.02.025

    authors: Girnun GD,Naseri E,Vafai SB,Qu L,Szwaya JD,Bronson R,Alberta JA,Spiegelman BM

    更新日期:2007-05-01 00:00:00

  • Does CSF1R Blockade Turn into Friendly Fire?

    abstract::In this issue of Cancer Cell, Kumar et al. describe how CSF1R blockade induces not only an expected deprivation of tumor-associated macrophages, but also an accumulation of tumor-infiltrating polymorphonuclear mononuclear cells caused by Cxcl-1 released from cancer-associated fibroblasts. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.10.012

    authors: Greten TF

    更新日期:2017-11-13 00:00:00

  • Long Noncoding RNAs in Cancer Pathways.

    abstract::Genome-wide cancer mutation analyses are revealing an extensive landscape of functional mutations within the noncoding genome, with profound effects on the expression of long noncoding RNAs (lncRNAs). While the exquisite regulation of lncRNA transcription can provide signals of malignant transformation, we now underst...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccell.2016.03.010

    authors: Schmitt AM,Chang HY

    更新日期:2016-04-11 00:00:00

  • Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

    abstract::Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, ...

    journal_title:Cancer cell

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ccr.2011.11.023

    authors: Van der Veldt AA,Lubberink M,Bahce I,Walraven M,de Boer MP,Greuter HN,Hendrikse NH,Eriksson J,Windhorst AD,Postmus PE,Verheul HM,Serné EH,Lammertsma AA,Smit EF

    更新日期:2012-01-17 00:00:00

  • β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

    abstract::Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating β-catenin le...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.10.030

    authors: Damsky WE,Curley DP,Santhanakrishnan M,Rosenbaum LE,Platt JT,Gould Rothberg BE,Taketo MM,Dankort D,Rimm DL,McMahon M,Bosenberg M

    更新日期:2011-12-13 00:00:00

  • Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

    abstract::Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion of pre-malignant cells via transcriptional silencing of proliferation-related genes due to decoration of their promoters with repressive trimethylated histone H3 lysine 9 (H3K9) marks. We show here that structurally distinct H3K9-active d...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.01.002

    authors: Yu Y,Schleich K,Yue B,Ji S,Lohneis P,Kemper K,Silvis MR,Qutob N,van Rooijen E,Werner-Klein M,Li L,Dhawan D,Meierjohann S,Reimann M,Elkahloun A,Treitschke S,Dörken B,Speck C,Mallette FA,Zon LI,Holmen SL,Peeper DS

    更新日期:2018-02-12 00:00:00

  • EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

    abstract::EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type EGFR...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.09.004

    authors: Fan QW,Cheng CK,Gustafson WC,Charron E,Zipper P,Wong RA,Chen J,Lau J,Knobbe-Thomsen C,Weller M,Jura N,Reifenberger G,Shokat KM,Weiss WA

    更新日期:2013-10-14 00:00:00

  • Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7.

    abstract::Monosomy 7 and interstitial deletion of 7q (-7/7q-) are well-recognized nonrandom chromosomal abnormalities frequently found among patients with myelodysplastic syndromes (MDSs) and myeloid leukemias. We previously identified candidate myeloid tumor suppressor genes (SAMD9, SAMD9-like = SAMD9L, and Miki) in the 7q21.3...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.08.011

    authors: Nagamachi A,Matsui H,Asou H,Ozaki Y,Aki D,Kanai A,Takubo K,Suda T,Nakamura T,Wolff L,Honda H,Inaba T

    更新日期:2013-09-09 00:00:00

  • Optimal gene expression analysis by microarrays.

    abstract::DNA microarrays make possible the rapid and comprehensive assessment of the transcriptional activity of a cell, and as such have proven valuable in assessing the molecular contributors to biological processes and in the classification of human cancers. The major challenge in using this technology is the analysis of it...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00181-2

    authors: Miller LD,Long PM,Wong L,Mukherjee S,McShane LM,Liu ET

    更新日期:2002-11-01 00:00:00

  • No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.

    abstract::Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human ther...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2014.12.010

    authors: Lux A,Nimmerjahn F

    更新日期:2015-01-12 00:00:00

  • A New Role for Lyn in the CLL Microenvironment.

    abstract::The role of Lyn, both a positive and a negative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well characterized. In this issue of Cancer Cell, Nguyen et al. demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2016.09.018

    authors: Dong S,Byrd JC

    更新日期:2016-10-10 00:00:00

  • Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

    abstract::We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the pre...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.11.004

    authors: Packer LM,Rana S,Hayward R,O'Hare T,Eide CA,Rebocho A,Heidorn S,Zabriskie MS,Niculescu-Duvaz I,Druker BJ,Springer C,Marais R

    更新日期:2011-12-13 00:00:00

  • CHAF1B Overexpression: A Brake for the Differentiation of Leukemia Cells.

    abstract::In this issue of Cancer Cell, Volk et al. report that overexpression of CHAF1B displaces myeloid transcription factors from chromatin, and deletion of CHAF1B promotes differentiation of leukemia cells and suppresses leukemogenesis in a murine model, revealing a causal role of and an unexpected mechanism for CHAF1B ove...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2018.10.011

    authors: Li Q,Zhang X,Zhang Z

    更新日期:2018-11-12 00:00:00

  • Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

    abstract::8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with t...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(04)00053-4

    authors: Roumiantsev S,Krause DS,Neumann CA,Dimitri CA,Asiedu F,Cross NC,Van Etten RA

    更新日期:2004-03-01 00:00:00

  • HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.

    abstract::HIF-2alpha promotes von Hippel-Lindau (VHL)-deficient renal clear cell carcinoma (RCC) tumorigenesis, while HIF-1alpha inhibits RCC growth. As HIF-1alpha antagonizes c-Myc function, we hypothesized that HIF-2alpha might enhance c-Myc activity. We demonstrate here that HIF-2alpha promotes cell-cycle progression in hypo...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.02.006

    authors: Gordan JD,Bertout JA,Hu CJ,Diehl JA,Simon MC

    更新日期:2007-04-01 00:00:00

  • Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

    abstract::Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer "hallmarks" through downstream activation of the gp130/STAT3 signaling pathway. However, we show that the related cytokine IL-11 has a stronger correlation with elevated STAT3 activation in human gastrointestinal...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.06.017

    authors: Putoczki TL,Thiem S,Loving A,Busuttil RA,Wilson NJ,Ziegler PK,Nguyen PM,Preaudet A,Farid R,Edwards KM,Boglev Y,Luwor RB,Jarnicki A,Horst D,Boussioutas A,Heath JK,Sieber OM,Pleines I,Kile BT,Nash A,Greten FR,McKe

    更新日期:2013-08-12 00:00:00

  • Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. To investigate the cellular origin(s) of this cancer, we determined the effect of PDAC-relevant gene mutations in distinct cell types of the adult pancreas. We show that a subpopulation of Pdx1-expressing cells is susceptible to onco...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.09.027

    authors: Gidekel Friedlander SY,Chu GC,Snyder EL,Girnius N,Dibelius G,Crowley D,Vasile E,DePinho RA,Jacks T

    更新日期:2009-11-06 00:00:00

  • Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.

    abstract::Hepatocyte I kappaB kinase beta (IKK beta) inhibits hepatocarcinogenesis by suppressing accumulation of reactive oxygen species (ROS) and liver damage, whereas JNK1 activation promotes ROS accumulation, liver damage, and carcinogenesis. We examined whether hepatocyte p38 alpha, found to inhibit liver carcinogenesis, a...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.06.016

    authors: Sakurai T,He G,Matsuzawa A,Yu GY,Maeda S,Hardiman G,Karin M

    更新日期:2008-08-12 00:00:00

  • An animal model of MYC-driven medulloblastoma.

    abstract::Medulloblastoma (MB) is the most common malignant brain tumor in children. Patients whose tumors exhibit overexpression or amplification of the MYC oncogene (c-MYC) usually have an extremely poor prognosis, but there are no animal models of this subtype of the disease. Here, we show that cerebellar stem cells expressi...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.12.021

    authors: Pei Y,Moore CE,Wang J,Tewari AK,Eroshkin A,Cho YJ,Witt H,Korshunov A,Read TA,Sun JL,Schmitt EM,Miller CR,Buckley AF,McLendon RE,Westbrook TF,Northcott PA,Taylor MD,Pfister SM,Febbo PG,Wechsler-Reya RJ

    更新日期:2012-02-14 00:00:00

  • Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

    abstract::To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identified mitochondrial translation inhibition as the mechanism of tigecycline-mediated lethality. Tigecycline selective...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.10.015

    authors: Skrtić M,Sriskanthadevan S,Jhas B,Gebbia M,Wang X,Wang Z,Hurren R,Jitkova Y,Gronda M,Maclean N,Lai CK,Eberhard Y,Bartoszko J,Spagnuolo P,Rutledge AC,Datti A,Ketela T,Moffat J,Robinson BH,Cameron JH,Wrana J,Eaves

    更新日期:2011-11-15 00:00:00

  • Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.

    abstract::Two recurrent mutations, K27M and G34R/V, within histone variant H3.3 were recently identified in ∼50% of pHGGs. Both mutations define clinically and biologically distinct subgroups of pHGGs. Here, we provide further insight about the dominant-negative effect of K27M mutant H3.3, leading to a global reduction of the r...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.10.006

    authors: Bender S,Tang Y,Lindroth AM,Hovestadt V,Jones DT,Kool M,Zapatka M,Northcott PA,Sturm D,Wang W,Radlwimmer B,Højfeldt JW,Truffaux N,Castel D,Schubert S,Ryzhova M,Seker-Cin H,Gronych J,Johann PD,Stark S,Meyer J,Mil

    更新日期:2013-11-11 00:00:00

  • ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.

    abstract::Myeloid-derived suppressor cells (MDSCs) play a major role in cancer. MDSC expansion is closely associated with tumor progression, but molecular mechanisms of this expansion remain poorly understood. In this issue of Cancer Cell, Strauss and colleagues describe the roles of the nuclear receptor ROR1C in the regulation...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2015.07.007

    authors: Gabrilovich D,Nefedova Y

    更新日期:2015-08-10 00:00:00

  • Impact of COVID-19 Pandemic on Cancer Research.

    abstract::The COVID-19 pandemic is profoundly changing cancer researchers and cancer research. Leaders from different fields and at different career stages share their perspectives. ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.10.007

    authors: Zon L,Gomes AP,Cance WG,Ribas A,Tuveson D,Postel-Vinay S,Massard C,Barlési F

    更新日期:2020-11-09 00:00:00

  • Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.

    abstract::Ependymoma is the third most common pediatric tumor with posterior fossa group A (PFA) being its most aggressive subtype. Ependymomas are generally refractory to chemotherapies and thus lack any effective treatment. Here, we report that elevated expression of CXorf67 (chromosome X open reading frame 67), which frequen...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.10.009

    authors: Han J,Yu M,Bai Y,Yu J,Jin F,Li C,Zeng R,Peng J,Li A,Song X,Li H,Wu D,Li L

    更新日期:2020-12-14 00:00:00

  • Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

    abstract::The co-engagement of fragment crystallizable (Fc) gamma receptors (FcγRs) with the Fc region of recombinant immunoglobulin monoclonal antibodies (mAbs) and its contribution to therapeutic activity has been extensively studied. For example, Fc-FcγR interactions have been shown to be important for mAb-directed effector ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.05.005

    authors: Waight JD,Chand D,Dietrich S,Gombos R,Horn T,Gonzalez AM,Manrique M,Swiech L,Morin B,Brittsan C,Tanne A,Akpeng B,Croker BA,Buell JS,Stein R,Savitsky DA,Wilson NS

    更新日期:2018-06-11 00:00:00

  • Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

    abstract::Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of resist...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.01.001

    authors: Iorns E,Turner NC,Elliott R,Syed N,Garrone O,Gasco M,Tutt AN,Crook T,Lord CJ,Ashworth A

    更新日期:2008-02-01 00:00:00

  • Paradoxical Puma Prohibits Pyruvate Pumps to Prime Pathology.

    abstract::PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers. In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carci...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2019.01.016

    authors: Green DR

    更新日期:2019-02-11 00:00:00